Disease modifying treatments (DMTs) for dementia are on the horizon. On 19 May 2021, NHS South East Clinical Delivery and Networks held a webinar to discuss the potential impact of DMTs for Alzheimer’s disease (AD) on South East clinical pathways.
The webinar aimed to:
• Share recent DMT trial results
• Discus potential impact on the clinical pathway
• Raise awareness of the opportunities and challenges involved in DMT delivery
Subsequent to the webinar on the 7 June 2021, the FDA approved Aducanumab for use in Alzheimer’s disease in the United States. In the UK, the MHRA and NICE are considering a UK approach. The horizon has come one step closer.
Find out more here: [ Ссылка ]
